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46
Recently, graphene and its derivatives have attracted an overwhelming interest for 47 potential medical or biological applications such as biosensors, cellular imaging, and 48 drug delivery [1] [2] [3] [4] [5] [6] [7] [8] [9] . Graphene based nanomaterials possess large specific surface areas 49 (theoretical value ~ 2630 m 2 g -1 ) [2, 10] and are able to complex with aromatic drugs via 50 π-π stacking and/or hydrophobic interaction [11, 12] for excellent drug storage property 51 [13] . Moreover, drugs loaded on graphene are highly stable to avoid any premature 52 release outside the target cell. One challenge is that graphene-based materials are easy 53 to agglomerate in buffer or cell medium to significantly decrease the drug loading 54 surface areas and thus reducing the cellular uptakes. It has been reported that graphene 55 and its derivative nanomaterials can be functionalized with polyethylene glycol (PEG) 56 [6, 14, 15] , polyethylenimine (PEI) [16] , gelatin [17] , chitosan [18] or sulfonic acid groups 57 [13] via covalent or noncovalent strategies for good dispersion and stability in 58 physiological solutions. Further conjugation with targeting ligands such as folic acid 59 [13, 19, 20] or Ritusan (anti-CD20) [14] can enhance the internalization into specific cell 60 types for an improved therapeutic efficacy. However, as many drug targets are 61 localized to subcellular compartments, the cell specific targeting with this approach is 62 still not sufficient and leads to either drug sequestration in endocytotic pathways or 63 pervasive drug distribution throughout a cell. Thus, an efficient subcellular targeting 64 strategy is very challenging but is highly demanded to achieve high therapeutic 65 efficacy in clinical applications [21] [22] [23] .
4
Many anticancer drugs such as doxorubicin (DOX), camptothecin (CPT) and 67 cisplatin kill cancer cells by intercalating nuclear DNA for direct damage or inhibiting 68 topoisomerase involved in DNA replication [24] [25] [26] [27] . [29] . The internalization ability of HER2 can have an efficient uptake of the 84 anti-HER2 antibodies or their conjugates [30] . 85 It is discovered that anti-HER2 conjugated rGO-PLL nanocarriers allow a rapid that of the rGO solution (II), whereas GO solution (I) exhibits a distinct brown colour.
189
FTIR spectra (Fig. 1b) FESEM images show that the rGO-PLL nanosheets (Fig. 1c) are much rougher 196 covering with condensed PLL particles as compared to the plain rGO (Fig. 1d) (Fig. S1 ).
212
It is postulated that DOX can be efficiently loaded on the rGO based nanocarriers 213 via π-π stacking and hydrophobic interactions, and we expect these interactions to be stronger than the charge repulsions. The DOX loading capacities of rGO-PLL and 215
anti-HER2-rGO-PLL are measured to be 41.2% and 37.2%, respectively (Fig.S2a) .
216
The slightly lower loading capacity for anti-HER2-rGO-PLL as compared to rGO-PLL 217 might be due to the slightly increased steric hindrance for DOX molecules to interact 218 with the rGO surfaces after the conjugation with antibodies. Overall, these two 219 nanocarriers exhibit loading capacities lower than unmodified GO/rGO, [7] but much 220 higher than conventional drug carriers such as polymer and silica nanoparticles.
[34]
221
Negligible DOX releases were observed from both samples after three day incubation 222 in PBS (Fig.S2b) . This confirms the stability of DOX on rGO-PLL and 223
anti-HER2-rGO-PLL, and further suggests that DOX can be protected in the 224 bloodstream before reaching the target tumour site.
225
As shown in Fig. 2a while the anti-HER2-rGO-PLL nanocarrier itself has negligible cytotoxicity against 240 MCF7/HER2 cells even at a high concentration of 80 g mL -1 (Fig.S3) . These results
241
show that anti-HER2 labelled nanocarrier greatly enhances anti-cancer efficacy and (FRET), [35] while releasing DOX from the nanocarriers upon isopropanol addition can 252 recover the fluorescence (Fig.S4 ).
253
As shown in Fig. 3a anti-HER2-rGO-PLL/DOX into MCF7/HER2 cells (Fig. 3a) . On the contrary, for the The cell uptake mechanisms of the nanocarriers were subsequently studied to identify 295 the internalization pathways utilized and explain the efficient nuclear drug 296 accumulation. Endocytic uptake is an energy-dependent mechanism that can be 297 strongly inhibited by lowering the temperature.
[37] We first investigated if the cellular 298 uptakes of anti-HER2 labelled and non-labelled rGO-PLL nanocarriers were 299 energy-dependent. Upon reducing the incubation temperature from 37 o C to 4 o C, the 300 cellular uptake of anti-HER2 labelled rGO-PLL nanocarriers was also significantly 301 reduced ( Fig. 6a & b) , indicating that anti-HER2-rGO-PLL is internalized via energy-dependent pathways. On the contrary, the cellular uptake of non-labelled 303 rGO-PLL nanocarriers was not significantly affected by temperature reduction (Fig. 6c 304 & d), suggesting an energy-independent uptake route.
305
To further elucidate the cellular uptake pathways, we studied the nanocarrier uptake affected by any of these inhibitors, which agree with its energy-independent nature of 309 uptake (Fig. 7a) . In contrast, anti-HER2-rGO-PLL is only significantly affected by 310 cytochalasin D (Fig. 7b) , displaying a ~ 45% reduction in the cellular uptake. 
